GT201700124A - FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP - Google Patents

FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP

Info

Publication number
GT201700124A
GT201700124A GT201700124A GT201700124A GT201700124A GT 201700124 A GT201700124 A GT 201700124A GT 201700124 A GT201700124 A GT 201700124A GT 201700124 A GT201700124 A GT 201700124A GT 201700124 A GT201700124 A GT 201700124A
Authority
GT
Guatemala
Prior art keywords
lixisenatida
glargine
formulation
fixed relationship
insulin
Prior art date
Application number
GT201700124A
Other languages
Spanish (es)
Inventor
Souhami Elisabeth
Silvestre Louise
Original Assignee
Sanofi Aventis Deutschlan Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54848560&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201700124(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschlan Gmbh filed Critical Sanofi Aventis Deutschlan Gmbh
Publication of GT201700124A publication Critical patent/GT201700124A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EL OBJETO DE LA PRESENTE INVENCIÓN ES UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE (A) LIXISENATIDA O/Y UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA MISMA Y (B) INSULINA GLARGINA O/Y UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA MISMA, EN LA QUE EL COMPUESTO (B) Y EL COMPUESTO (A) ESTÁN PRESENTES EN UNA RELACIÓN DE APROXIMADAMENTE 2,6 A APROXIMADAMENTE 3,4 U DE COMPUESTO (B) POR UG DE COMPUESTO (A).THE OBJECT OF THE PRESENT INVENTION IS A PHARMACEUTICAL COMPOSITION THAT INCLUDES (A) LIXISENATIDA OR / AND A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND (B) INSULIN GLARGINE OR / AND A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, IN WHICH (B) ) AND THE COMPOUND (A) ARE PRESENT IN A RELATIONSHIP OF APPROXIMATELY 2.6 TO APPROXIMATELY 3.4 U OF COMPOSITE (B) PER UG OF COMPOUND (A).

GT201700124A 2014-12-12 2017-06-12 FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP GT201700124A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14197685 2014-12-12
EP15193940 2015-11-10

Publications (1)

Publication Number Publication Date
GT201700124A true GT201700124A (en) 2018-11-26

Family

ID=54848560

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201700124A GT201700124A (en) 2014-12-12 2017-06-12 FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP

Country Status (32)

Country Link
US (5) US9950039B2 (en)
EP (1) EP3229828B1 (en)
JP (1) JP6970615B2 (en)
KR (1) KR102578030B1 (en)
CN (1) CN107206058A (en)
AU (1) AU2015359376B2 (en)
BR (1) BR112017012406A2 (en)
CA (1) CA2970200A1 (en)
CL (1) CL2017001483A1 (en)
CO (1) CO2017006898A2 (en)
CR (1) CR20170314A (en)
DK (1) DK3229828T3 (en)
EC (1) ECSP17044282A (en)
ES (1) ES2949095T3 (en)
FI (1) FI3229828T3 (en)
GT (1) GT201700124A (en)
HR (1) HRP20230470T1 (en)
HU (1) HUE062573T2 (en)
IL (1) IL252803B (en)
LT (1) LT3229828T (en)
MA (1) MA41138B1 (en)
MX (1) MX2017007699A (en)
NZ (1) NZ733670A (en)
PE (1) PE20171622A1 (en)
PH (1) PH12017501084A1 (en)
PL (1) PL3229828T3 (en)
RS (1) RS64300B1 (en)
SG (1) SG11201704678SA (en)
SI (1) SI3229828T1 (en)
TN (1) TN2017000235A1 (en)
TW (1) TWI758239B (en)
WO (1) WO2016092026A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101820024B1 (en) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 Combination of an insulin and a GLP-1 agonist
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
CN115779207A (en) 2016-03-24 2023-03-14 特鲁德尔医学国际公司 Respiratory care system with electronic indicator
WO2018055539A1 (en) * 2016-09-22 2018-03-29 Wockhardt Limited Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue
JP7240004B2 (en) * 2017-07-27 2023-03-15 アドシア A composition in the form of an aqueous solution injection comprising at least human insulin A21G and a phagocytic glucagon suppressor
US20210093698A1 (en) * 2019-09-13 2021-04-01 Sanofi Treatment of type 2 diabetes mellitus
US20220397560A1 (en) * 2021-06-10 2022-12-15 Thermo Finnigan Llc Auto outlier injection identification

Family Cites Families (383)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US975286A (en) * 1910-03-05 1910-11-08 Charles H A F L Ross Trigger mechanism.
GB835638A (en) 1956-12-01 1960-05-25 Novo Terapeutisk Labor As Insulin crystal suspensions having a protracted effect
GB840870A (en) 1957-08-03 1960-07-13 Novo Terapeutisk Labor As Improvements in or relating to insulin preparations
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US3758683A (en) 1971-04-30 1973-09-11 R Jackson Insulin product
US4153689A (en) 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1554157A (en) 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
GB1527605A (en) 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
JPS6033474B2 (en) 1978-05-11 1985-08-02 藤沢薬品工業株式会社 Novel hyaluronidase BMP-8231 and its production method
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3064888D1 (en) 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
JPS55153712A (en) 1979-05-18 1980-11-29 Kao Corp Insulin pharmaceutical preparation and its production
DE3033127A1 (en) 1980-09-03 1982-04-08 Hoechst Ag, 6000 Frankfurt NEW INSULIN ANALOG
US4367737A (en) 1981-04-06 1983-01-11 George Kozam Multiple barrel syringe
WO1983000288A1 (en) 1981-07-17 1983-02-03 Balschmidt, Per A stable aqueous, therapeutic insulin preparation and a process for preparing it
NL193099C (en) 1981-10-30 1998-11-03 Novo Industri As Stabilized insulin solution.
DE3326473A1 (en) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt PHARMACEUTICAL AGENT FOR TREATING THE DIABETES MELLITUS
DE3326472A1 (en) 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt NEW INSULIN DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AND PHARMACEUTICAL AGENTS FOR TREATING THE DIABETES MELLITUS
DE3327709A1 (en) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt INSULIN DERIVATIVE CRYSTAL SUSPENSIONS, METHOD FOR THE PRODUCTION AND USE THEREOF
DE3333640A1 (en) 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt METHOD FOR THE PRODUCTION OF INSULIN DERIVATIVES, THE B-CHAIN C-TERMINAL EXTENDED, NEW BASICALLY MODIFIED INSULIN DERIVATIVES, THE MEANS CONTAINING THEM AND THEIR USE
CA1244347A (en) 1984-05-29 1988-11-08 Eddie H. Massey Stabilized insulin formulations
US4839341A (en) 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
DE3576120D1 (en) 1984-06-09 1990-04-05 Hoechst Ag INSULIN PREPARATIONS, METHOD FOR THE PRODUCTION AND USE THEREOF.
DE3440988A1 (en) 1984-11-09 1986-07-10 Hoechst Ag, 6230 Frankfurt METHOD FOR CLEAVING PEPTIDES AND PROTEINS ON THE METHIONYL BOND
DK347086D0 (en) 1986-07-21 1986-07-21 Novo Industri As NOVEL PEPTIDES
US5008241A (en) 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK113585D0 (en) 1985-03-12 1985-03-12 Novo Industri As NEW PEPTIDES
CA1274774A (en) 1985-04-15 1990-10-02 Kenneth S. Su Method for administering insulin
US4689042A (en) 1985-05-20 1987-08-25 Survival Technology, Inc. Automatic medicament ingredient mixing and injecting apparatus
DE3526995A1 (en) 1985-07-27 1987-02-05 Hoechst Ag FUSION PROTEINS, METHOD FOR THEIR PRODUCTION AND THEIR USE
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4960702A (en) 1985-09-06 1990-10-02 Codon Methods for recovery of tissue plasminogen activator
DE3541856A1 (en) 1985-11-27 1987-06-04 Hoechst Ag EUKARYOTIC FUSION PROTEINS, THEIR PRODUCTION AND USE, AND MEANS FOR CARRYING OUT THE PROCESS
US5496924A (en) 1985-11-27 1996-03-05 Hoechst Aktiengesellschaft Fusion protein comprising an interleukin-2 fragment ballast portion
DE3636903A1 (en) 1985-12-21 1987-07-02 Hoechst Ag FUSION PROTEINS WITH EUKARYOTIC BALLASTES
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
DE3544295A1 (en) 1985-12-14 1987-06-19 Bayer Ag THERMOPLASTIC MOLDS WITH HIGH CROSS-CURRENT RESISTANCE
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
NZ223630A (en) 1987-02-25 1989-11-28 Novo Industri As Insulin derivative and pharmaceutical compositions
US5034415A (en) 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
DE3726655A1 (en) 1987-08-11 1989-02-23 Hoechst Ag METHOD FOR ISOLATING BASIC PROTEINS FROM PROTEIN MIXTURES CONTAINING SUCH BASIC PROTEINS
DK257988D0 (en) 1988-05-11 1988-05-11 Novo Industri As NEW PEPTIDES
US6875589B1 (en) 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
DE3827533A1 (en) 1988-08-13 1990-02-15 Hoechst Ag PHARMACEUTICAL PREPARATION FOR TREATING THE DIABETES MELLITUS
US4923162A (en) 1988-09-19 1990-05-08 Fleming Matthew C Radiation shield swivel mount
DE3837825A1 (en) 1988-11-08 1990-05-10 Hoechst Ag NEW INSULIN DERIVATIVES, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM
US5225323A (en) 1988-11-21 1993-07-06 Baylor College Of Medicine Human high-affinity neurotransmitter uptake system
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
DK134189D0 (en) 1989-03-20 1989-03-20 Nordisk Gentofte INSULIN COMPOUNDS
JP2582186B2 (en) 1989-05-04 1997-02-19 サウザン リサーチ インスティチュート Encapsulation method and its products
GR1005153B (en) 1989-08-29 2006-03-13 The General Hospital Corporation Fusion proteins their preparation and use
US5227293A (en) 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use
US5358857A (en) 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
CN1020944C (en) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 Fastening element
EP0532546B1 (en) 1990-05-10 1998-03-18 Bechgaard International Research And Development A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
US5397771A (en) 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
DK155690D0 (en) 1990-06-28 1990-06-28 Novo Nordisk As NEW PEPTIDES
DK10191D0 (en) 1991-01-22 1991-01-22 Novo Nordisk As HIS UNKNOWN PEPTIDES
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
CA2038597A1 (en) 1991-03-19 1992-09-20 Jose P. Garzaran A method and a pharmaceutical preparation for treating pain
US5614219A (en) 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
US6468959B1 (en) 1991-12-05 2002-10-22 Alfatec-Pharm Gmbh Peroral dosage form for peptide containing medicaments, in particular insulin
CH682806A5 (en) 1992-02-21 1993-11-30 Medimpex Ets Injection device.
CH682805A5 (en) 1992-02-24 1993-11-30 Medimpex Ets Display device for an injection device.
DK36392D0 (en) 1992-03-19 1992-03-19 Novo Nordisk As USE OF CHEMICAL COMPOUND
US5846747A (en) 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
DK39892D0 (en) 1992-03-25 1992-03-25 Bernard Thorens PEPTIDE
US5253785A (en) 1992-04-02 1993-10-19 Habley Medical Technology Corp. Variable proportion dispenser
EP0600372B1 (en) 1992-12-02 1997-02-05 Hoechst Aktiengesellschaft Process for the preparation of proinsulin with correctly linked cystin bridges
CA2151134A1 (en) 1992-12-18 1994-07-07 Ronald Eugene Chance Insulin analogs
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5478323A (en) 1993-04-02 1995-12-26 Eli Lilly And Company Manifold for injection apparatus
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE122006000017I1 (en) 1993-06-21 2006-06-29 Novo Nordisk As ASP-B28-insulin crystals
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5534488A (en) 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
EP1649850A1 (en) 1993-11-19 2006-04-26 Alkermes Controlled Therapeutics Inc. II Preparation of biodegradable microparticles containing a biologically active agent
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
IT1265271B1 (en) 1993-12-14 1996-10-31 Alcatel Italia BASEBAND PREDISTRITORTION SYSTEM FOR THE ADAPTIVE LINEARIZATION OF POWER AMPLIFIERS
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE4405179A1 (en) 1994-02-18 1995-08-24 Hoechst Ag Method of obtaining insulin with correctly connected cystine bridges
DE4405388A1 (en) 1994-02-19 1995-08-24 Hoechst Ag Process for the preparation of polyalkyl-1-oxa-diazaspirodecane compounds
KR100419037B1 (en) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 Methods of delivery of insulin through the lungs and their composition
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5559094A (en) 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
EP0779806B2 (en) 1994-09-09 2008-04-16 Takeda Pharmaceutical Company Limited Sustained release preparation containing metal salt of a peptide
US5879584A (en) 1994-09-10 1999-03-09 The Procter & Gamble Company Process for manufacturing aqueous compositions comprising peracids
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
AR002976A1 (en) 1995-03-31 1998-05-27 Lilly Co Eli PARENTERAL PHARMACEUTICAL FORMULATIONS OF LONG-TERM EFFECT OF INSULIN; CRYSTALS OF SUCH ANALOGUES APPLICABLE IN SUCH FORMULATIONS AND PROCEDURE OF THE FORMULATIONS MENTIONED
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
WO1996034882A1 (en) 1995-05-05 1996-11-07 Eli Lilly And Company Single chain insulin with high bioactivity
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US6143718A (en) 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
WO1996041606A2 (en) 1995-06-08 1996-12-27 Therexsys Limited Improved pharmaceutical compositions for gene therapy
ATE268591T1 (en) 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd METHOD FOR PRODUCING DELAYED RELEASE PREPARATIONS
JPH11292787A (en) 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd Transucosal preparation containing physiologically active peptide
DE19545257A1 (en) 1995-11-24 1997-06-19 Schering Ag Process for the production of morphologically uniform microcapsules and microcapsules produced by this process
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
DE19637230A1 (en) 1996-09-13 1998-03-19 Boehringer Mannheim Gmbh Truncated versions of exendin peptide(s) for treating diabetes
CN1183158C (en) 1996-06-05 2005-01-05 罗赫诊断器材股份有限公司 Exendin analogues, processes for their preparation and medicaments containing them
CZ297937B6 (en) 1996-06-20 2007-05-02 Novo Nordisk A/S Aqueous insulin preparation containing sodium chloride, method and use thereof
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
ATE369146T1 (en) 1996-06-20 2007-08-15 Novo Nordisk As INSULIN PREPARATION WITH MANNITOL
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
DE69739172D1 (en) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc REGULATION OF GASTROINTESTINAL MOBILITY
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
CA2468374C (en) 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
DE122007000044I2 (en) 1997-01-07 2011-05-05 Amylin Pharmaceuticals Inc USE OF EXEDINES AND THEIR ANTAGONISTS TO REDUCE FOOD CONSUMPTION
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
CA2279836A1 (en) 1997-02-05 1998-08-13 1149336 Ontario Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
HUP0000547A3 (en) 1997-03-20 2002-11-28 Novo Nordisk As Zinc free insulin crystals for use in pulmonary compositions
US6043214A (en) 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
DE69810481T2 (en) 1997-06-13 2003-09-25 Genentech Inc STABILIZED ANTIBODY FORMULATION
DE19726167B4 (en) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, process for its preparation and pharmaceutical preparation containing it
WO1999007404A1 (en) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
DE19735711C2 (en) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Process for the preparation of a precursor to insulin or insulin derivatives with correctly linked cystine bridges
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
JP2001521006A (en) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー Insoluble insulin composition
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
ES2202910T3 (en) 1997-11-12 2004-04-01 Alza Corporation COMPOSITIONS OF REGULATED PHARMACES FOR TRANSDERMAL ADMINISTRATION BY ELECTRICAL TRANSPORTATION
ATE381939T1 (en) 1997-11-14 2008-01-15 Amylin Pharmaceuticals Inc NOVEL EXENDIN AGONISTS
ATE383867T1 (en) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc NOVEL EXENDIN AGONISTS
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
AU1870099A (en) 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
DE69936446T2 (en) 1998-02-13 2008-03-06 Amylin Pharmaceuticals, Inc., San Diego INOTROPIC AND DIETIC EFFECTS OF EXENDIN AND GLP-1
SK12412000A3 (en) 1998-02-23 2002-05-09 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999046283A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
ATE269103T1 (en) 1998-03-13 2004-07-15 Novo Nordisk As STABILIZED AQUEOUS GLUCAGON SOLUTIONS CONTAINING DETERGENTS
ATE413889T1 (en) 1998-06-05 2008-11-15 Nutrinia Ltd INSULIN ENRICHED INFANT NUTRITION SUPPLEMENT
DE69926007T2 (en) 1998-10-07 2005-12-29 Medical College Of Georgia Research Institute, Inc. GLUCOSE-DEPENDENT, INSULINOTROPIC PEPTIDE FOR USE AS OSTEOTROPES HORMON
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
EP1121145B1 (en) 1998-10-16 2002-04-17 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
DE69920767T2 (en) 1998-10-16 2006-02-02 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary administration
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
WO2000029013A1 (en) 1998-11-18 2000-05-25 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
EP1609478A1 (en) 1999-01-14 2005-12-28 Amylin Pharmaceuticals, Inc. Exendin agonist peptide formulations
DE19908041A1 (en) 1999-02-24 2000-08-31 Hoecker Hartwig Covalently bridged insulin dimers
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2007204498A (en) 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd Long-term stabilized formulations
JP2000247903A (en) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd Long-term stabilized pharmaceutical preparation
US6227819B1 (en) 1999-03-29 2001-05-08 Walbro Corporation Fuel pumping assembly
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
CN1372570A (en) 1999-04-30 2002-10-02 安米林药品公司 Modified exendin and exendin agonists
SI1180121T1 (en) 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
CA2375914A1 (en) 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
DE19930631A1 (en) 1999-07-02 2001-01-11 Clemens Micheler Spraying device for injecting at least two liquid therapeutic agents, in particular insulin
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
CN1174741C (en) 1999-09-21 2004-11-10 Rtp药品公司 Surface modified particulate compositions of biologically active substances
DE19947456A1 (en) 1999-10-02 2001-04-05 Aventis Pharma Gmbh New synthetic derivatives of the C-peptide of proinsulin, useful in the preparation of human insulin or insulin analogs in high yield
PT1491208E (en) 1999-10-04 2010-05-12 Novartis Vaccines & Diagnostic Stabilized liquid pharmaceutical compositions containing tfpi
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
JP5183844B2 (en) 1999-11-03 2013-04-17 ブリストル−マイヤーズ スクイブ カンパニー How to treat diabetes
EP1523993A1 (en) 1999-12-16 2005-04-20 Eli Lilly & Company Polypeptide compositions with improved stability
PT1242121E (en) 1999-12-16 2005-05-31 Lilly Co Eli POLIPEPTIDIC COMPOSITIONS WITH IMPROVED STABILITY
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
US20010012829A1 (en) 2000-01-11 2001-08-09 Keith Anderson Transepithelial delivery GLP-1 derivatives
AU2353701A (en) 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2001093837A2 (en) 2000-06-08 2001-12-13 Eli Lilly And Company Protein powder for pulmonary delivery
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
JP5161412B2 (en) 2000-09-18 2013-03-13 サノス・バイオサイエンス・アクティーゼルスカブ Methods of using GLP-1 and GLP-2 peptides
KR100508695B1 (en) 2001-02-13 2005-08-17 한국과학기술연구원 Formulation for oral delivery of insulin and preparation method thereof
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
DE10108211A1 (en) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Use of fusion proteins, the N-terminal portion of which consists of a hirudin derivative, for the production of recombinant proteins via secretion by yeast
DE10108100A1 (en) 2001-02-20 2002-08-29 Aventis Pharma Gmbh Use of super-secretable peptides in processes for their preparation and parallel improvement of the export of one or more other polypeptides of interest
DE10108212A1 (en) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusion protein for the secretion of valuable protein in bacterial supernatants
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
WO2002067868A2 (en) 2001-02-26 2002-09-06 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
DE10114178A1 (en) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
ATE443082T1 (en) 2001-04-02 2009-10-15 Novo Nordisk As INSULIN PRECURSORS AND METHOD FOR THE PRODUCTION THEREOF
CN1160122C (en) 2001-04-20 2004-08-04 清华大学 Method of preparing oil-phase oral insulin preparation
US20030026872A1 (en) 2001-05-11 2003-02-06 The Procter & Gamble Co. Compositions having enhanced aqueous solubility and methods of their preparation
WO2003002021A2 (en) 2001-06-29 2003-01-09 The Regents Of The University Of California Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs
FR2827604B1 (en) 2001-07-17 2003-09-19 Sanofi Synthelabo NOVEL 1-PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOL-2- ONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU2002317599B2 (en) 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
CA2452044A1 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
AU2002335046A1 (en) 2001-10-19 2003-05-06 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
US20050123509A1 (en) 2001-10-19 2005-06-09 Lehrman S. R. Modulating charge density to produce improvements in the characteristics of spray-dried proteins
ATE464390T1 (en) 2001-11-19 2010-04-15 Novo Nordisk As METHOD FOR PRODUCING INSULIN COMPOUNDS
EP2436393A1 (en) 2001-12-19 2012-04-04 Millennium Pharmaceuticals, Inc. Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor
KR20040070237A (en) 2001-12-20 2004-08-06 일라이 릴리 앤드 캄파니 Insulin Molecule Having Protracted Time Action
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
WO2003066084A1 (en) 2002-02-07 2003-08-14 Novo Nordisk A/S Use of glp-1 compound for treatment of critically ill patients
US20100069293A1 (en) 2002-02-27 2010-03-18 Pharmain Corporation Polymeric carrier compositions for delivery of active agents, methods of making and using the same
TWI351278B (en) 2002-03-01 2011-11-01 Nisshin Pharma Inc Agent for preventing and treating of liver disease
WO2003094951A1 (en) 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
ES2360182T3 (en) 2002-05-07 2011-06-01 Novo Nordisk A/S SOLUBLE FORMULATIONS THAT INCLUDE MONOMERIC INSULIN AND ACILATED INSULIN.
US7115563B2 (en) 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
DE10227232A1 (en) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
WO2004005342A1 (en) 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 and methods for treating diabetes
DE10235168A1 (en) 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Process for the purification of preproinsulin
US20040092590A1 (en) 2002-09-27 2004-05-13 Linda Arterburn Glycemic control for prediabetes and/or diabetes Type II using docosahexaenoic acid
US7544657B2 (en) 2002-10-02 2009-06-09 Zealand Pharma A/S Stabilized Exendin-4 compounds
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
US20050209142A1 (en) 2002-11-20 2005-09-22 Goran Bertilsson Compounds and methods for increasing neurogenesis
ES2359720T3 (en) 2002-11-20 2011-05-26 Neuronova Ab COMPOUNDS AND METHODS TO INCREASE THE NEUROGENESIS.
CN1413582A (en) 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 Dimethyldiguanide hydrochloride enteric solubility tablet and its preparation method
WO2004050115A2 (en) 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
GB0309154D0 (en) 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
GB0304822D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
WO2004078196A1 (en) 2003-03-04 2004-09-16 The Technology Development Company Ltd. Oral insulin composition and methods of making and using thereof
WO2004080480A1 (en) 2003-03-11 2004-09-23 Novo Nordisk A/S Pharmaceutical preparations comprising acid-stabilised insulin
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
BRPI0409600A (en) 2003-04-29 2006-04-18 Lilly Co Eli insulin analog, composition, method of treating hyperglycemia, and proinsulin analogue
CA2527743A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
DE10325567B4 (en) 2003-06-05 2008-03-13 Mavig Gmbh Radiation protection arrangement with separable enclosure
EP1667718A4 (en) 2003-08-29 2007-05-02 Centocor Inc Method of promoting graft survival with anti-tissue factor antibodies
JP5518282B2 (en) 2003-09-01 2014-06-11 ノヴォ ノルディスク アー／エス Stable peptide formulation
WO2005023291A2 (en) 2003-09-11 2005-03-17 Novo Nordisk A/S Use of glp1-agonists in the treatment of patients with type i diabetes
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
JP4800959B2 (en) 2003-11-13 2011-10-26 ノヴォ ノルディスク アー／エス Soluble pharmaceutical composition for parenteral administration comprising GLP-1 peptide and short-acting insulin peptide for the treatment of diabetes and bulimia
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
US20050201978A1 (en) 2003-11-17 2005-09-15 Lipton James S. Tumor and infectious disease therapeutic compositions
WO2005061222A1 (en) 2003-12-22 2005-07-07 Novo Nordisk A/S Transparent, flexible, impermeable plastic container for storage of pharmaceutical liquids
US20060210614A1 (en) 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
EP1701714A2 (en) 2004-01-07 2006-09-20 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
US20070027063A1 (en) 2004-01-12 2007-02-01 Mannkind Corporation Method of preserving the function of insulin-producing cells
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080248999A1 (en) 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
EA011583B1 (en) 2004-03-31 2009-04-28 Сентокор, Инк. Human glp-1 mimetibodies, compositions, methods and uses
EP1758597B1 (en) 2004-05-20 2012-09-12 Diamedica Inc. Use of drug combinations for treating insulin resistance
WO2005117948A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
NZ551603A (en) 2004-06-24 2010-11-26 Incyte Corp N-substituted piperidines and their use as pharmaceuticals
EP1906991A2 (en) 2004-06-28 2008-04-09 Novo Nordisk A/S Use of glp-1 receptor agonists and/or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i, diabetes type ii and impaired pancreatic beta-cell function
EP1771573A4 (en) 2004-07-21 2009-02-18 Ambrx Inc Biosynthetic polypeptides utilizing non-naturally encoded amino acids
CN101010425B (en) 2004-08-13 2010-05-26 霍夫曼-拉罗奇有限公司 C-terminal modification of polypeptides
DE102004043153B4 (en) 2004-09-03 2013-11-21 Philipps-Universität Marburg Invention relating to GLP-1 and exendin
US20060073213A1 (en) 2004-09-15 2006-04-06 Hotamisligil Gokhan S Reducing ER stress in the treatment of obesity and diabetes
EP1791554A2 (en) 2004-09-17 2007-06-06 Novo Nordisk A/S Pharmaceutical compositions containing insulin and insulinotropic peptide
JP2006137678A (en) 2004-11-10 2006-06-01 Shionogi & Co Ltd Interleukin-2 composition
EP1814581B1 (en) 2004-11-12 2016-03-16 Novo Nordisk A/S Stable formulations of peptides comprising an acylated glp-1 analogue and a basal insuline
AU2005303777B2 (en) 2004-11-12 2010-12-16 Novo Nordisk A/S Stable formulations of insulinotropic peptides
DE102004058306A1 (en) 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Process for the preparation of carboxy-terminally amidated peptides
SE0402976L (en) 2004-12-03 2006-06-04 Mederio Ag Medical product
CA2592065A1 (en) 2004-12-22 2007-04-26 Centocor, Inc. Glp-1 agonists, compositions, methods and uses
US7879361B2 (en) 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
US20090142338A1 (en) 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
ATE509634T1 (en) 2005-04-08 2011-06-15 Amylin Pharmaceuticals Inc PHARMACEUTICAL FORMULATIONS CONTAINING INCRETIN PEPTIDE AND APROTIC-POLAR SOLVENT
JP5235661B2 (en) 2005-05-25 2013-07-10 ノボ・ノルデイスク・エー／エス Stabilized polypeptide preparation
DK1888031T3 (en) 2005-06-06 2013-02-18 Camurus Ab GLP-1 analog formulations
JP5416969B2 (en) 2005-06-27 2014-02-12 ニュートゥリー カンパニー リミテッド Method for preventing and treating diseases mediated by PPAR using macelignan
US20080227847A1 (en) 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
HUE045165T2 (en) 2005-08-19 2019-12-30 Amylin Pharmaceuticals Llc Exendin for treating diabetes and reducing body weight
EP1937297A2 (en) 2005-09-08 2008-07-02 Gastrotech Pharma A/S Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
BRPI0616054B8 (en) 2005-09-14 2021-05-25 Sanofi Aventis Deutschland process for the preparation of insulin, an insulin analogue or an insulin derivative, porcine trypsin, method for its production, DNA and vector
RU2440143C2 (en) 2005-09-20 2012-01-20 Новартис Аг Application of dpp-iv inhibitor for reduction of glycemia acute exacerbation
US20070078510A1 (en) 2005-09-26 2007-04-05 Ryan Timothy R Prosthetic cardiac and venous valves
KR101105871B1 (en) 2005-09-27 2012-01-16 주식회사 엘지생명과학 hFSF Aqueous Formulation
DE102005046113A1 (en) 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Preparation of C-amidated peptides, useful as pharmaceuticals, by reaction between precursor peptides in presence of enzyme with activity of trypsin, also new reaction products
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
EP1933884B1 (en) 2005-10-11 2017-09-06 Huntington Medical Research Institutes Imaging agents and methods of use thereof
US8530447B2 (en) 2005-10-24 2013-09-10 Nestec S.A. Dietary fiber formulation and method of administration
AP2008004447A0 (en) 2005-11-30 2008-04-30 Generex Pharm Inc Orally absorbed pharmaceutical formulation and method of administration
US20100029558A1 (en) 2005-12-06 2010-02-04 Bristow Cynthia L Alpha1 proteinase inhibitor peptides methods and use
EP1968644B1 (en) 2005-12-16 2012-06-27 Nektar Therapeutics Polymer conjugates of glp-1
RU2008132149A (en) 2006-01-05 2010-02-10 Юниверсити Оф Юта Рисерч Фаундейшн (Us) METHODS AND COMPOSITIONS RELATING TO THE IMPROVED PROPERTIES OF PHARMACOLOGICAL MEANS, DIRECTLY ACCORDING TO THE NERVOUS SYSTEM
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
US20090324701A1 (en) 2006-01-20 2009-12-31 Diamedica, Inc. Compositions containing (s)-bethanechol and their use in the treatment of insulin resistance, type 2 diabetes, glucose intolerance and related disorders
US20070191271A1 (en) 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
EP1986674A4 (en) 2006-02-13 2009-11-11 Nektar Therapeutics Methionine-containing protein or peptide compositions and methods of making and using
WO2007098479A2 (en) 2006-02-21 2007-08-30 University Of Medicine And Dentistry Of New Jersey Localized insulin delivery for bone healing
US20090054305A1 (en) 2006-03-15 2009-02-26 Novo Nordisk A/S Mixtures of Amylin and Insulin
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
JP2009532422A (en) 2006-04-03 2009-09-10 ノボ・ノルデイスク・エー／エス GLP-1 peptide agonist
CN101454019A (en) 2006-04-12 2009-06-10 百达尔公司 Rapid acting and long acting insulin combination formulations
JP2009533460A (en) 2006-04-13 2009-09-17 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Pharmaceutical composition of hGLP-1, exendin-4 and analogs thereof
EP2021368A4 (en) 2006-06-08 2010-01-20 Diabecore Medical Inc Derivatized insulin oligomers
DE102006031962A1 (en) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidated insulin glargine
EP2076242B8 (en) 2006-07-27 2013-02-20 Nektar Therapeutics Aerosolizable formulation comprising insulin for pulmonary delivery
CA2660835A1 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable propperties
EP2057189B1 (en) 2006-08-25 2013-03-06 Novo Nordisk A/S Acylated exendin-4 compounds
BRPI0716134A2 (en) 2006-09-07 2013-09-17 Nycomed Gmbh combination treatment for diabetes mellitus
JP5864834B2 (en) 2006-09-22 2016-02-17 ノボ・ノルデイスク・エー／エス Protease resistant insulin analogue
ES2402172T3 (en) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Suspension formulation of insulinotropic peptides and uses thereof
WO2008145323A1 (en) 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
JP2010528792A (en) 2007-06-14 2010-08-26 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Double chamber carpul
DK2167169T4 (en) 2007-06-14 2016-05-30 Sanofi Aventis Deutschland Tokammerkarpule with accessories
US9173991B2 (en) 2007-07-02 2015-11-03 Roche Diabetes Care, Inc. Device for drug delivery
EP2581441A1 (en) 2007-08-09 2013-04-17 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
US8575096B2 (en) 2007-08-13 2013-11-05 Novo Nordisk A/S Rapid acting insulin analogues
CN101366692A (en) 2007-08-15 2009-02-18 江苏豪森药业股份有限公司 Stable Exenatide formulation
GB0717399D0 (en) 2007-09-07 2007-10-17 Uutech Ltd Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
GB0717388D0 (en) 2007-09-07 2007-10-17 Uutech Ltd Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
RU2010114049A (en) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) CGRP AS A THERAPEUTIC
SI2219607T1 (en) 2007-11-01 2012-09-28 Merck Serono Sa Liquid LH formulations
ES2543393T3 (en) 2007-11-08 2015-08-18 Novo Nordisk A/S Insulin derivative
JP5241849B2 (en) 2007-11-16 2013-07-17 ノボ・ノルデイスク・エー／エス Pharmaceutical composition comprising insulin and insulinotropic peptide
CN101444618B (en) 2007-11-26 2012-06-13 杭州九源基因工程有限公司 Pharmaceutical preparation containing exenatide
US20090186819A1 (en) 2007-12-11 2009-07-23 Marieve Carrier Formulation of insulinotropic peptide conjugates
CN101951957A (en) 2008-01-04 2011-01-19 百达尔公司 Insulin discharges the insulin preparation as the function of the glucose level of tissue
DE102008003568A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh New insulin analogs useful for treating diabetes
BRPI0907119A2 (en) 2008-01-09 2015-07-14 Sanofi Aventis Deutschland Insulin derivatives having an extremely delayed time action profile
KR20100111682A (en) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 Novel insulin derivatives having an extremely delayed time-action profile
DE102008003566A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh New insulin analogs useful for treating diabetes
CN110433136A (en) 2008-02-08 2019-11-12 泰哈麦克斯总部英国有限公司 The liquid preparation of follicle-stimulating hormone (FSH)
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
BRPI0822775A2 (en) 2008-02-19 2015-06-30 Biocon Ltd Method of obtaining a purified biologically active heterologous protein.
TWI394580B (en) 2008-04-28 2013-05-01 Halozyme Inc Super fast-acting insulin compositions
EP2288918A1 (en) 2008-05-23 2011-03-02 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist bioassays
TWI451876B (en) 2008-06-13 2014-09-11 Lilly Co Eli Pegylated insulin lispro compounds
EP2307038A4 (en) 2008-06-27 2013-03-27 Univ Duke Therapeutic agents comprising elastin-like peptides
US8574214B2 (en) 2008-08-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Cartridge and needle system therefor
WO2010028055A1 (en) 2008-09-02 2010-03-11 Biodel, Inc. Insulin with a basal release profile
MX2011002372A (en) 2008-09-10 2011-04-04 Genentech Inc Compositions and methods for the prevention of oxidative degradation of proteins.
CN101670096B (en) 2008-09-11 2013-01-16 杭州九源基因工程有限公司 Medicinal preparation containing exenatide
NZ592113A (en) 2008-10-15 2012-04-27 Intarcia Therapeutics Inc Highly concentrated drug particles, formulations, suspensions and uses thereof
KR101820024B1 (en) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 Combination of an insulin and a GLP-1 agonist
DE102008053048A1 (en) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
JP2009091363A (en) 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Stabilized aqueous injectable solution of pth
JP5677321B2 (en) 2009-02-04 2015-02-25 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Medical device and method for providing information for blood glucose control
NZ594044A (en) 2009-02-13 2014-08-29 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
EP2435061A4 (en) 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc Glp-1 receptor agonist compounds for sleep enhancement
US20120241356A1 (en) 2009-07-06 2012-09-27 Sanofi-Aventis Deutschland Gmbh Heat- and vibration-stable insulin preparations
US20120232002A1 (en) 2009-07-06 2012-09-13 Sanofi-Aventis Deutschland Gmbh Slow-acting insulin preparations
EP2451437B1 (en) 2009-07-06 2016-11-02 Sanofi-Aventis Deutschland GmbH Aqueous preparations comprising methionine
US8709400B2 (en) 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
SG178195A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Long acting insulin composition
US8642548B2 (en) 2009-08-07 2014-02-04 Mannkind Corporation Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
EP2329848B2 (en) 2009-11-13 2019-06-19 Sanofi-Aventis Deutschland GmbH Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes
PL2324853T3 (en) 2009-11-13 2016-01-29 Sanofi Aventis Deutschland Lixisenatide as add-on to metformin in the treatment of diabetes type 2
ES2534191T3 (en) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US20110118178A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
US20110118180A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
HUE037735T2 (en) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION COMPRISING desPro36Exendin-4(1-39)-Lys6-NH2 AND METHIONINE
WO2011075623A1 (en) 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids
EP2359843A1 (en) 2010-01-21 2011-08-24 Sanofi Pharmaceutical composition for treating a metabolic syndrome
WO2011103575A1 (en) 2010-02-22 2011-08-25 Case Western Reserve University Long-acting insulin analogue preparations in soluble and crystalline forms
AR081066A1 (en) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd INSULIN CONJUGATE WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
AR080884A1 (en) 2010-04-14 2012-05-16 Sanofi Aventis INSULIN-SIRNA CONJUGATES
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2011144674A2 (en) 2010-05-20 2011-11-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
EP2389945A1 (en) * 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
US9085757B2 (en) 2010-06-17 2015-07-21 Regents Of The University Of Minnesota Production of insulin producing cells
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
US20130137645A1 (en) 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
BR112013004756B1 (en) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland use of ave0010 for the manufacture of a medication for the treatment of type 2 diabetes mellitus
CA2815419A1 (en) 2010-10-27 2012-05-03 Novo Nordisk A/S Treating diabetes melitus using insulin injections administered with varying injection intervals
WO2012065996A1 (en) 2010-11-15 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN
WO2012066086A1 (en) 2010-11-17 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN
WO2012080320A1 (en) 2010-12-14 2012-06-21 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
EP2670427A1 (en) 2011-02-02 2013-12-11 Sanofi-Aventis Deutschland GmbH Prevention of hypoglycaemia in diabetes mellitus type 2 patients
WO2012125569A2 (en) 2011-03-11 2012-09-20 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
US20120277147A1 (en) 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US8735349B2 (en) 2011-05-13 2014-05-27 Sanofi-Aventis Deutschland Gmbh Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
US20130040878A1 (en) 2011-05-13 2013-02-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in the treatment of diabetes type 2 patients
US9821032B2 (en) * 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
MX362527B (en) 2011-05-13 2019-01-23 Sanofi Aventis Deutschland Lixisenatide and metformin for treatment of diabetes type 2.
JP2014520159A (en) 2011-06-24 2014-08-21 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Method for treating diabetes with sustained-release preparation of GLP-1 receptor agonist
RU2650616C2 (en) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Pharmaceutical combination for use in glycemic control in patients with type 2 diabetes mellitus
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
SI2763690T1 (en) 2011-10-04 2016-03-31 Sanofi-Aventis Deutschland Gmbh Lixisenatide for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
EP2763691A1 (en) 2011-10-04 2014-08-13 Sanofi-Aventis Deutschland GmbH Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
MY170713A (en) 2011-10-28 2019-08-27 Sanofi Aventis Deutschland Treatment protocol of diabetes type 2
US8901484B2 (en) 2012-04-27 2014-12-02 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
AR092862A1 (en) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF PROLONGED ACTION INSULIN AND AN INSULINOTROPIC PEPTIDE AND PREPARATION METHOD
TWI641381B (en) 2013-02-04 2018-11-21 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
GB201303771D0 (en) 2013-03-04 2013-04-17 Midatech Ltd Nanoparticles peptide compositions
SG11201509781YA (en) * 2013-06-17 2015-12-30 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
AR098168A1 (en) 2013-10-25 2016-05-04 Sanofi Sa STABLE FORMULATION OF GLULISINE INSULIN

Also Published As

Publication number Publication date
US20190060411A1 (en) 2019-02-28
CO2017006898A2 (en) 2017-10-10
US9950039B2 (en) 2018-04-24
MA41138A (en) 2017-10-17
FI3229828T3 (en) 2023-05-29
US20190381145A1 (en) 2019-12-19
AU2015359376A1 (en) 2017-07-27
BR112017012406A2 (en) 2018-07-31
HUE062573T2 (en) 2023-11-28
CA2970200A1 (en) 2016-06-16
KR20170094361A (en) 2017-08-17
SI3229828T1 (en) 2023-06-30
DK3229828T3 (en) 2023-06-26
IL252803A0 (en) 2017-08-31
AU2015359376B2 (en) 2021-09-09
US20230037934A1 (en) 2023-02-09
RS64300B1 (en) 2023-07-31
KR102578030B1 (en) 2023-09-14
ES2949095T3 (en) 2023-09-25
JP2017538705A (en) 2017-12-28
MA41138B1 (en) 2023-07-31
US20160199452A1 (en) 2016-07-14
SG11201704678SA (en) 2017-07-28
HRP20230470T1 (en) 2023-07-21
CN107206058A (en) 2017-09-26
LT3229828T (en) 2023-06-12
TN2017000235A1 (en) 2018-10-19
IL252803B (en) 2022-04-01
US20210128692A1 (en) 2021-05-06
NZ733670A (en) 2021-12-24
PH12017501084A1 (en) 2017-10-18
ECSP17044282A (en) 2017-11-30
JP6970615B2 (en) 2021-11-24
WO2016092026A1 (en) 2016-06-16
TW201642899A (en) 2016-12-16
EP3229828B1 (en) 2023-04-05
CR20170314A (en) 2017-10-20
EP3229828A1 (en) 2017-10-18
TWI758239B (en) 2022-03-21
CL2017001483A1 (en) 2018-02-23
PL3229828T3 (en) 2023-07-31
PE20171622A1 (en) 2017-11-02
MX2017007699A (en) 2017-09-18

Similar Documents

Publication Publication Date Title
GT201700124A (en) FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP
GT201600137A (en) COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBE AND ROSUVASTATIN
CL2015000295A1 (en) Compounds derived from alkylpyrimidine; pharmaceutical composition that includes them; Use for the treatment of viral infections and other diseases.
MX2020011104A (en) Pharmaceutical compositions of therapeutically active compounds.
MX2016008979A (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives.
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
PE20180411A1 (en) PHARMACEUTICAL FORMULATIONS INCLUDING TENOFOVIR AND EMTRICITABIN
SV2017005515A (en) NASAL DUST FORMULATIONS FOR THE TREATMENT OF HYPOGLYCEMIA
CL2016001918A1 (en) Heteroaryl amides as protein aggregation inhibitors
CL2016001587A1 (en) Derivative based on 1,2-naphthoquinone and method of preparation thereof.
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
BR112016015851A2 (en) STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ASPART
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
AR094707A1 (en) COMPOUND OF QUINAZOLIN-4-AMINA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE TREATMENT OF A DISEASE MEDIATED BY THE RIP2 KINASE
CL2016003023A1 (en) "Compounds derived from (benzyl-piperazin-1-yl) (tetrahydrofuran-carbonyl or tetrahydropyran-carbonyl) substituted, rorg modulators; pharmaceutical composition comprising them; and its use in the treatment of multiple sclerosis and ankylosing spondylitis. ” pct
CL2016002879A1 (en) Pharmaceutical compositions for treating infectious diseases
CL2016000542A1 (en) Composition comprising hydroxypropyl chitosan together with pharmaceutically acceptable excipients and / or adjuvants; useful in the treatment of onychomycosis.
CL2018003514A1 (en) Peptides for the inhibition of infections caused by a parasite.
AR102978A1 (en) FORMULATION OF FIXED INSULIN GLARGINE / LIXISENATIDA
TR201721065A2 (en) Lyophilized pharmaceutical formulations comprising dexmedetomidine
AR100354A1 (en) DANIRIXINE PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFECTIOUS DISEASES
IN2014CH00149A (en)
IN2014CH00035A (en)